Richard Edwards, MD
Family Medicine · Jennings, LANPI 1003059403
Payments from drug & device makers
Across 123 payments — averaging $48.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$4K
- AbbVie$527
- Boehringer Ingelheim$289
- AstraZeneca$251
- Astellas Pharma US Inc$115
- Supernus Pharmaceuticals, Inc.$101
- plus $547 from 19 others
What the payments were for
- Speaking & faculty fees$3,55060%
- Food & beverage$2,26538%
- Education$952%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 28 | $4,079 |
| AbbVie(2 entities) | 34 | $527 |
| Boehringer Ingelheim | 7 | $289 |
| AstraZeneca | 14 | $251 |
| Astellas Pharma US Inc | 2 | $115 |
| Supernus Pharmaceuticals, Inc. | 6 | $101 |
| Intuitive Surgical | 1 | $91 |
| Novo Nordisk | 5 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $61 |
| Amgen | 3 | $45 |
| Sumitomo Pharma America, Inc. | 3 | $39 |
| Kyowa Kirin, Inc. | 1 | $32 |
| GSK | 2 | $25 |
| Lilly USA, LLC | 2 | $25 |
| Tactile Systems Technology Inc | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Novartis | 1 | $13 |
| Biomerieux Inc | 1 | $13 |
| Biofire Diagnostics, LLC | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Shire North American Group Inc | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Otsuka America Pharmaceutical, Inc. | 1 | $12 |
| Adlon Therapeutics L.p. | 1 | $12 |
| Abbott | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,910 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 163 | $188,341 |
| OzempicSemaglutide | 168 | $187,062 |
| JardianceEmpagliflozin | 195 | $107,173 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 13 | $97,932 |
| FarxigaDapagliflozin Propanediol | 122 | $82,654 |
| EliquisApixaban | 149 | $73,908 |
| RybelsusSemaglutide | 69 | $67,493 |
| Xigduo XrDapaglifloz Propaned/Metformin | 81 | $56,735 |
| JanuviaSitagliptin Phosphate | 118 | $54,795 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 62 | $51,417 |
| XareltoRivaroxaban | 79 | $50,823 |
| VraylarCariprazine Hcl | 31 | $44,299 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $41,382 |
| TrulicityDulaglutide | 43 | $40,056 |
| XifaxanRifaximin | 25 | $39,375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $76 | $254,555237 claims |
| Lilly USA, LLCMounjaro, Trulicity | $25 | $228,396206 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat, Tradjenta, Synjardy Xr | $289 | $143,360259 claims |
| PfizerEliquis, Nurtec Odt | $4,079 | $86,120160 claims |
| AbbVieVraylar, Linzess | $527 | $83,43999 claims |
| AstraZenecaFarxiga | $251 | $82,654122 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix | $25 | $81,986161 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $13 | $51,41762 claims |
| Astellas Pharma US IncMyrbetriq | $115 | $24,11185 claims |
| NovartisEntresto | $13 | $17,25620 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $39 | $9,35720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Jennings
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
- Clint WilsonBossier City$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.